Creo Medical Regulatory News (CREO)

Creo Medical Group plc

("Creo" or the "Company")

Posting of Annual Reports and Accounts

Notice of Annual General Meeting

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that its Report and Accounts for the 12 month period ended 31 December 2019, together with its Notice of Annual General Meeting ("AGM") and a Form of Proxy, will be mailed out to shareholders today.

These documents are available on the Company's website: https://investors.creomedical.com/investors/reports-and-presentations/2020 

The AGM will be held at 10 a.m. on Wednesday 24 June 2020. In light of the UK Government's guidance and legislation in relation to the COVID-19 situation, including to limit travel and public gatherings, and the likelihood that this advice may remain in place at the time of the AGM, the Company and the Chairman have determined that only two representatives from the board shall attend in person at the AGM, both of which shall be either a shareholder and/or shall hold letters of representation to ensure that the AGM is quorate in accordance with the Company's articles of association.

There will be no trading updates or board presentations and the business to be conducted at the AGM is considered, by the Company, to be administrative in nature. The Resolutions to be proposed at the AGM shall be held on a poll and not on a show of hands as the Company believe that this is the best and fairest way to ensure that the votes of all Shareholders can be taken into account. As such, shareholders should note that they are not entitled to attend the Company's AGM in person unless notified via the Company's website https://investors.creomedical.com and the RNS.

All shareholders are to vote by submitting a Form of Proxy, in line with the instructions set out in the Notice of AGM document.

Enquiries:

About Creo Medical 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions. 

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. 

For more information about Creo Medical please see our website, investors.creomedical.com